Your location:
Homepage
-
-
-
Mycophenolate Mofetil (MMF)

Mycophenolate Mofetil (MMF)

Product description

1、Nomenclature
English name:Mycophenolate Mofetil (MMF) 


2、Structural formula

Molecular

Structure

 

Molecular formula:C23H31NO7        
Molecular weight:433.50       
CAS No.: 128794-94-5


3、Mechanism and clinical use:
Mycophenolate Mofetil is synthesized by Mycophenolic Acid and 4-(2-Hydroxyethyl) morpholine. It is immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor. It is used for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

 

Mycophenolate Mofetil has more strong inhibition effect for EB virus induced B lymphoblast transformation. 1, When it is used in combination with other immunosuppressive drugs, it will increase the risk of lymphoma and other malignant tumor (especially skin cancer), and overinhibition to immune system may increase infection opportunity. 2, When it is used in combination with acyclovir or ganciclovir, there is no obvious change of blood concentration of MPA; when the combination used for patients with renal function impairment, blood concentration of acyclovir or ganciclovir gets to rise. 3, Sulfinpyrazone may interfere this drug’s secretion from kidney tubules, if MMF is used in combination with sulfinpyrazone, this drug’s toxicity is enhanced. 4, When MMF is used in combination with antacid agents which contains magnesium or aluminum (such as magnesium hydroxide and aluminium hydroxide), the absorption of this drug is to be reduced. 5, Echinacea purpurea may excite immune system to reduce this drug’s efficacy. 6, Ferrous drugs may reduce the absorption and efficacy of this drug. 7, If the drug is used in combination with drugs that may disturb enterohepatic cycling (such as colestyramine), may reduce efficacy. 8, It can not be excluded the possibility of changing pharmacokinetics parameters of oral contraceptives after long time administration. This may reduce efficacy of oral contraceptives. 9, During taking of this drug, vaccination of live attenuated vaccines should be avoided, and other vaccines may have no efficacy during the administration period of this drug.
 

On Dec. 2019, Mycophenolate Mofetil passed GMP re certification .
On Dec.2020, API Mycophenolate Mofetil was granted “written confirmation for active substance exported to EU”.


4、Packaging size specification
Inner package: double-layers polyethylene bag and aluminum foil bag.
Outer package: fiber drum.
Packaging size: 20 Kg/drum

 

More products

Bacitracin

企业精神

YOU CAN MAKE FOR YOURSELF

Bacitracin

Bacitracin Zinc

企业精神

YOU CAN MAKE FOR YOURSELF

Bacitracin Zinc

Fusidic Acid

企业精神

YOU CAN MAKE FOR YOURSELF

Fusidic Acid

Sodium Fusidate

企业精神

YOU CAN MAKE FOR YOURSELF

Sodium Fusidate

Cyclosporin

企业精神

YOU CAN MAKE FOR YOURSELF

Cyclosporin

Mycophenolate Mofetil (MMF)

企业精神

YOU CAN MAKE FOR YOURSELF

Mycophenolate Mofetil (MMF)

Tacrolimus

企业精神

YOU CAN MAKE FOR YOURSELF

Tacrolimus

Capecitabine

企业精神

YOU CAN MAKE FOR YOURSELF

Capecitabine

Erlotinib Hydrochloride

企业精神

YOU CAN MAKE FOR YOURSELF

Erlotinib Hydrochloride

Pioglitazone  Hydrochloride

企业精神

YOU CAN MAKE FOR YOURSELF

Pioglitazone Hydrochloride

Mycophenolic Acid

企业精神

YOU CAN MAKE FOR YOURSELF

Mycophenolic Acid

Joyang Laboratories

Marketing Department Tel:

Company address:

No. 9 Haidu North Road, Sheyang Economic Development Zone, Jiangsu Province

Copyright: Joyang Laboratories    京ICP备88888888号-1         Website construction: Xinnet